Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events. - Wikidata - wikimedia - TriplyDB

Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events.

Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events.

http://www.wikidata.org/entity/Q50511478

about

Mechanism of Platinum Derivatives Induced Kidney Injury Membrane transporters as mediators of Cisplatin effects and side effects.Cisplatin-induced renal injury is independently mediated by OCT2 and p53.Organic cation transporter variation and response to smoking cessation therapies Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 Proteins Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects.Polymorphic transporters and platinum pharmacodynamics Aging increases the susceptibility of cisplatin-induced nephrotoxicity Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs).Uptake carriers and oncology drug safety.Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice.Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney.The Role of Transporters in the Toxicity of Chemotherapeutic Drugs: Focus on Transporters for Organic Cations.Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?Xenobiotic transporters and kidney injury.Renal Drug Transporters and Drug Interactions.Abundance of Drug Transporters in the Human Kidney Cortex as Quantified by Quantitative Targeted Proteomics.Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study.Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans.Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review

P2860

Q26783436-929744A0-16BD-44B9-9A81-529EE7D53F89 Q30446860-C27FAF19-D239-4AF1-8763-7BF886F2F1B4 Q33992572-D6B3FD39-B3DC-4459-AA7F-6CEE2CC43546 Q34974830-19F8A1D4-C277-4BE4-A13A-967F75742A7D Q35795744-4DFBFA9B-5416-461A-BBE6-B50D5F9B9CED Q36737021-C25E671B-A213-4752-A78A-F9FB1BA53CE7 Q36995742-92951313-F291-4511-B2DC-F8F5B490F935 Q37219376-36501256-6ED3-4E1E-931A-01873C7BB6F1 Q37315965-1AC54444-0DFC-49B4-9344-F250AFDAA7D0 Q37663396-264882D9-B48B-47E5-B4A6-BD0683AFD303 Q37734911-93C399EE-66ED-4874-8A90-95F5C53A5D34 Q38084145-B2DB68BC-F35B-4A86-B2E2-AFD275981645 Q38888345-5786F364-E4DD-4F5E-8AAE-5ED4D142544A Q38888369-33D39FD8-8D05-4167-A8E4-3BB542CF2E3D Q39098252-7B70E74F-7228-4DC9-994C-483A7E0AA273 Q39140289-E149DB54-96C4-469B-8AC2-107D6CDE67D2 Q39398250-F3D67941-D1C3-4A37-97D6-D03433958F32 Q40264602-43E84FA6-EADA-426D-A911-9AD2A73C106F Q43585637-98FF55CD-DDF3-4156-962A-666B8D8CACAE Q47381902-EB46CC3B-A8FB-489A-A961-80E884009478 Q57490969-C7FF28F0-5A67-45BA-9DEF-0778353662F8

P2860

Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events.

http://www.wikidata.org/entity/Q50511478

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Effects of genetic variants in ...... platin-induced adverse events.

@en

Effects of genetic variants in ...... platin-induced adverse events.

@nl

type

label

Effects of genetic variants in ...... platin-induced adverse events.

@en

Effects of genetic variants in ...... platin-induced adverse events.

@nl

prefLabel

Effects of genetic variants in ...... platin-induced adverse events.

@en

Effects of genetic variants in ...... platin-induced adverse events.

@nl

P1433

Q50511478-3CA31F4F-0047-408F-9BF2-8F7955873D96

P1476

Q50511478-ADD1C5C6-B327-4E42-BFCB-C9814E799898

P2093

Q50511478-45715EDE-828F-4A88-AE6B-57DD2D5551E2

Q50511478-4932654A-0655-4448-8302-293CEE81ADA1

Q50511478-767AD9D7-416F-4922-8D26-996245C0E389

Q50511478-9066421D-94FE-4E99-9D83-7CDB730D5CAD

Q50511478-AE38E884-1F1D-4554-AA69-9A7F6CE86090

Q50511478-CD6CF133-A3B6-49A5-9384-60FBD9DD5102

Q50511478-E05077E5-1AA0-4DD6-AC9C-AF1A027FBC9F

Q50511478-E9D4E7A7-EBCF-4A60-A0A1-23A4BF1617DC

Q50511478-EA182235-C47B-4874-8EDF-DE5EBDA9BC5F

P2860

Q50511478-0A92EB6E-7FE8-404E-9FD2-6826B5C2415B

Q50511478-2ED9651A-C93C-4D66-952D-66969BCADD96

Q50511478-2F509C29-CFFD-427E-9817-E9B1C716E999

Q50511478-3152A84F-2A2C-44DF-B87D-AD664E45F7A3

Q50511478-37B3EC94-ADD6-4CB7-9BAE-1628FC5A930D

Q50511478-382EAF87-A692-4B1D-A31D-598C4962BF82

Q50511478-40CE1091-C77D-42D8-A82D-98081351A7AF

Q50511478-5870A313-9173-4F6F-98DF-3F48D986D016

Q50511478-5B51C45F-B4B0-43BA-BEE0-7F20B366AEF2

Q50511478-63C16EE2-BBFB-4E43-BF40-73D45F22560E

P2888

Q50511478-E91DA532-C5D3-4A19-9CFE-0DE779B96CF6

P304

Q50511478-9173A8A9-7CA9-4FF4-ABB9-2C3B192AA924

P31

Q50511478-3DB1C0A1-BA8E-40D8-B57B-A74D1764D4A1

P356

Q50511478-CDA0C28B-505F-4B10-AEDA-54AAC558EE2D

P433

Q50511478-D7DA8025-14DE-4C1B-8AA6-0D846B8B7E32

P478

Q50511478-050B0C2F-B0D9-4A32-9D98-9C2F566D4C00

P577

Q50511478-DB5C9BBF-87F1-4E7F-A4DC-B9DA5C4CEB2B

P698

Q50511478-A158E3C6-48E4-4485-8615-9A99A22CA178

P356

S10157-012-0638-Y

P1433

Clinical and experimental nephrology

P1476

Effects of genetic variants in ...... platin-induced adverse events.

@en

P2093

Akinobu Hamada

http://www.w3.org/2001/XMLSchema#string

Eiko Fukunaga

http://www.w3.org/2001/XMLSchema#string

Hideyuki Saito

http://www.w3.org/2001/XMLSchema#string

Kazufumi Iwata

http://www.w3.org/2001/XMLSchema#string

Keiji Aizawa

http://www.w3.org/2001/XMLSchema#string

Minoru Yoshida

http://www.w3.org/2001/XMLSchema#string

Misato Yoshimura

http://www.w3.org/2001/XMLSchema#string

Sachiko Jingami

http://www.w3.org/2001/XMLSchema#string

Saori Kamitsu

http://www.w3.org/2001/XMLSchema#string

P2860

A human transporter protein that mediates the final excretion step for toxic organic cations

Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H+ antiporter in the kidney

Cellular and molecular aspects of drug transport in the kidney.

Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function.

Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1

Protein kinase C-alpha and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na+ transport, and cisplatin-induced apoptosis in renal cells.

Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study.

Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity.

Revised equations for estimated GFR from serum creatinine in Japan

TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity.

P2888

s10157-012-0638-y

P304

843-851

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10157-012-0638-Y

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22569819

http://www.w3.org/2001/XMLSchema#string